Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2021 | Evaluating the LIPI for first line immunotherapy in NSCLC

Laura Mezquita, Hospital Clinic Barcelona, Barcelona, Spain, discusses an analysis of the applicability of the Lung Immune Prognostic Index (LIPI) to first line treatment of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI). The association of the LIPI with immunotherapy outcomes in the pretreated NSCLC setting has been previously established. Patients treated with ICI monotherapy, ICI combined with CTLA4-inhibitor, or ICI plus chemotherapy were identified for this retrospective analysis. Over 900 patients were enrolled and their LIPI scores were calculated and grouped. The results showed that LIPI scores were correlated with outcomes. The LIPI poor subgroup had a significantly worse overall survival than other subgroups and progression-free survival was correlated with LIPI scores in the overall study population. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.

Disclosures

Research grants/funding: Bristol Myers Squibb, Boehringer Ingelheim, Amgen
Advisory/Consultancy: Roche Diagnostics, Takeda
Honoraria: Bristol Myers Squibb, Tecnofarma, Roche
Travel/Accommodation/Expenses: Roche
Non-remunerated activity: AstraZeneca